Readers hoping to buy Amgen Inc. ( NASDAQ:AMGN ) for its dividend will need to make their move shortly, as the stock ...

Below is Validea's guru fundamental report for AMGEN INC (AMGN). Of the 22 guru strategies we follow, AMGN rates highest using our Shareholder Yield Investor model based on the published strategy ...

Amgen AMGN reported fourth-quarter 2024 adjusted ... However, weakness in some key brands like Otezla is a headwind. Also, sales of Amgen’s best-selling drugs, Prolia and Xgeva, are expected ...

Amgen (NASDAQ:AMGN) did what it was "supposed to do." By that, I mean it followed through on what its chart indicated it would do in response to earnings. I'll show what I mean below, but my ...

Opinions expressed by Forbes Contributors are their own. While HON and AMGN may offer little returns in the next three years, it is helpful to see how Honeywell’s Peers fare on metrics that matter.

Shares of Amgen Inc. AMGN shed 1.42% to $293.54 Friday, on what proved to be an all-around dismal trading session for the ...

Amgen (AMGN) came out with quarterly earnings of $5.31 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $4.71 per share a year ago. These figures ...

(see more details here) Amgen Inc. (NASDAQ:AMGN) is an innovator in human therapies ... medications Enbrel and Otezla are among the brand-name medications. The company launched its first cancer ...

Truist Financial analyst Srikripa Devarakonda maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $298.00. The company’s shares closed yesterday at $289.02.

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...